Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7512.091 | 1.0245 | 1.0558 | 0.8817 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7512.091 | 0.9643 | 0.9192 | 0.8817 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7512.091 | 1.0016 | 1.0036 | 0.8817 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.107 | uM | 7512.091 | 0.9857 | 0.9675 | 0.8817 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.533 | uM | 7512.091 | 1.0172 | 1.0391 | 0.8817 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 2.67 | uM | 7512.091 | 1.0240 | 1.0545 | 0.8817 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 13.3 | uM | 7512.091 | 1.0021 | 1.0048 | 0.8817 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 66.7 | uM | 7512.091 | 0.9106 | 0.7984 | 0.8817 | |
| MDA-MB-453 | TNBC | Luminal | Erlotinib | EGFR | ErbB | 0.0000853 | uM | 7515.092 | 0.9292 | 0.8815 | 1.2024 | |
| MDA-MB-453 | TNBC | Luminal | Erlotinib | EGFR | ErbB | 0.000427 | uM | 7515.092 | 0.8819 | 0.8015 | 1.2024 | |
| MDA-MB-453 | TNBC | Luminal | Erlotinib | EGFR | ErbB | 0.00213 | uM | 7515.092 | 0.9045 | 0.8398 | 1.2024 | |
| MDA-MB-453 | TNBC | Luminal | Erlotinib | EGFR | ErbB | 0.0107 | uM | 7515.092 | 0.8947 | 0.8233 | 1.2024 | |
| MDA-MB-453 | TNBC | Luminal | Erlotinib | EGFR | ErbB | 0.0533 | uM | 7515.092 | 0.9010 | 0.8339 | 1.2024 | |
| MDA-MB-453 | TNBC | Luminal | Erlotinib | EGFR | ErbB | 0.267 | uM | 7515.092 | 0.9129 | 0.8540 | 1.2024 | |
| MDA-MB-453 | TNBC | Luminal | Erlotinib | EGFR | ErbB | 1.33 | uM | 7515.092 | 0.9455 | 0.9090 | 1.2024 | |
| MDA-MB-453 | TNBC | Luminal | Erlotinib | EGFR | ErbB | 6.67 | uM | 7515.092 | 0.9062 | 0.8427 | 1.2024 | |
| MDA-MB-453 | TNBC | Luminal | Erlotinib | EGFR | ErbB | 33.3 | uM | 7515.092 | 0.6887 | 0.4666 | 1.2024 | |
| MDA-MB-453 | TNBC | Luminal | Erlotinib | EGFR | ErbB | 0.0000853 | uM | 7516.092 | 1.0336 | 1.0607 | 1.1035 | |
| MDA-MB-453 | TNBC | Luminal | Erlotinib | EGFR | ErbB | 0.000427 | uM | 7516.092 | 0.9325 | 0.8773 | 1.1035 | |
| MDA-MB-453 | TNBC | Luminal | Erlotinib | EGFR | ErbB | 0.00213 | uM | 7516.092 | 0.9852 | 0.9732 | 1.1035 | |
| MDA-MB-453 | TNBC | Luminal | Erlotinib | EGFR | ErbB | 0.0107 | uM | 7516.092 | 0.9853 | 0.9734 | 1.1035 | |
| MDA-MB-453 | TNBC | Luminal | Erlotinib | EGFR | ErbB | 0.0533 | uM | 7516.092 | 1.0268 | 1.0486 | 1.1035 | |
| MDA-MB-453 | TNBC | Luminal | Erlotinib | EGFR | ErbB | 0.267 | uM | 7516.092 | 1.0510 | 1.0921 | 1.1035 | |
| MDA-MB-453 | TNBC | Luminal | Erlotinib | EGFR | ErbB | 1.33 | uM | 7516.092 | 0.9475 | 0.9046 | 1.1035 | |
| MDA-MB-453 | TNBC | Luminal | Erlotinib | EGFR | ErbB | 6.67 | uM | 7516.092 | 0.9950 | 0.9910 | 1.1035 |